Evogene Reports Third Quarter 2015 Financial Results

Go back to Evogene Reports Third Quarter 2015 Financial Results

Evogene Ltd. (EVGN) Expects Delayed Evofuel commercialization; Piper Jaffray Cuts Price Target to $8

November 19, 2015 8:56 AM EST

Piper Jaffray reiterated a Neutral rating on Evogene Ltd (NYSE: EVGN), and cut the price target to $8.00 (from $12.00), following the company's 3Q earnings report .Evogene announced results relatively in-line with Piper Jaffray's expectations, where revenue and opex were only slightly higher due to more gene discovery being done in-house. Management now expects Evofuel commercialization to be delayed,... More

Evogene Ltd. (EVGN) Tops Q3 EPS by 2c

November 18, 2015 7:11 AM EST

Evogene Ltd. (NYSE: EVGN) reported Q3 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $3.31 million versus the consensus estimate of $3.5 million.

As of September 30, 2015, Evogene had $106.4 million in cash, short-term bank deposits and marketable securities,... More